In one study, fibroblast growth factor 21 (FGF21) attenuated TLR-4-triggered hepatocyte IL-17A expression, and anti-IL-17A treatment alleviated HCC nodule numbers in NASH mice. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.